Lot-to-lot variation of unfractionated heparin using the anti-factor Xa assay.

被引：0
|
作者：
Pullen, GE
Siegel, JE
Goodell, LA
机构：
[1] Robert Wood Johnson Univ Hosp, New Brunswick, NJ USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Newark, NJ 07103 USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2002年 / 118卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
95
引用
收藏
页码：648 / 649
页数：2
相关论文
共 50 条
  • [41] IS ANTI-FACTOR XA MONITORING BETTER THAN ACTIVATED PARTIALTHROMBOPLASTIN TIME (APTT) IN ACHIEVING THERAPEUTIC RESPONSE TO UNFRACTIONATED HEPARIN?
    Manzanades, Yuri
    NURSING IN CRITICAL CARE, 2021, 26 : 30 - 31
  • [42] MODIFIED ANTI-FACTOR XA CHROMOGENIC SUBSTRATE ASSAY FOR HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARINS
    HARENBERG, J
    ARZTLICHE LABORATORIUM, 1987, 33 (02): : 39 - 41
  • [43] Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children
    Greene, L. A.
    Law, C.
    Jung, M.
    Walton, S.
    Ignjatovic, V.
    Monagle, P.
    Raffini, L. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (09) : 1554 - 1557
  • [44] The anti-factor Xa range for low molecular weight heparin thromboprophylaxis
    Wei, Matthew Y.
    Ward, Salena M.
    HEMATOLOGY REPORTS, 2015, 7 (04) : 80 - 83
  • [45] HEPARIN AND LOW-MOLECULAR WEIGHT HEPARIN - IS ANTI-FACTOR XA ACTIVITY IMPORTANT
    LANE, DA
    RYAN, K
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1989, 114 (04): : 331 - 333
  • [46] Components of variability of the effect of activated partial thromboplastin time vs. anti-factor Xa on unfractionated heparin dose adjustments
    Guerrero, F.
    Faucher, A.
    Diemert, V
    Voisin, S.
    Sie, P.
    Riviere, Bura A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 380 - 381
  • [47] Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience
    Woods, Gary M.
    Stanek, Joseph
    Harrison, Sheilah
    Texter, Karen
    Kerlin, Bryce A.
    Dunn, Amy L.
    Kumar, Riten
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (07) : 576 - +
  • [48] Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assay's Limit of Detection?
    Wu, Alan H. B.
    Kavsak, Peter A.
    Aakre, Kristin Moberg
    Christenson, Robert H.
    Greene, Dina N.
    Apple, Fred S.
    Peacock, W. Frank
    Hollander, Judd E.
    de Lemos, James A.
    Morrow, David
    Januzzi, James
    Jaffe, Allan S.
    CLINICAL CHEMISTRY, 2020, 66 (09) : 1146 - 1149
  • [49] INFLUENCE OF ANTITHROMBIN DEFICIENCY AND ELEVATED FACTOR VIII ON HEPARIN ACTIVITY MEASURED BY APTT AND ANTI-FACTOR XA ASSAY IN VITRO
    Kostousov, Vadim
    Kim Nguyen
    Teruya, Jun
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2013, 35 : 72 - 73
  • [50] Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban
    von Horn, Henrik
    Rasmusson, Agnes
    Soderblom, Lisbeth
    Malmstrom, Rickard E.
    Antovic, Jovan
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2022, 44 (01) : 163 - 167
12345